Insys Therapeutics, Inc. 4

Accession 0001209191-15-027512

CIK 0001516479operating

View on SEC.gov Company Profile

Filed

Mar 17, 8:00 PM ET

Accepted

Mar 18, 4:49 PM ET

Size

31.6 KB

Accession

0001209191-15-027512

Insider Transaction Report

Form 4

Period: 2015-03-16

Insys Therapeutics, Inc.INSY

Babich Michael L

DirectorPresident and CEO

Transactions

Exercise/Conversion
Common Stock
2015-03-17$7.26/sh+27,400$198,924→ 230,152 total
Exercise/Conversion
Common Stock
2015-03-16$7.26/sh+1,845$13,395→ 250,352 total
Sale
Common Stock
2015-03-16$57.91/sh−8,224$476,252→ 242,128 total
Sale
Common Stock
2015-03-17$58.95/sh−1,600$94,320→ 202,752 total
Exercise/Conversion
Stock Option (right to buy)
2015-03-16−45,755→ 117,995 total
Exercise: $2.36Exp: 2022-12-26→ Common Stock (45,755 underlying)
Exercise/Conversion
Common Stock
2015-03-16$3.25/sh+30,000$97,500→ 202,752 total
Sale
Common Stock
2015-03-17$57.21/sh−12,500$715,125→ 217,652 total
Exercise/Conversion
Stock Option (right to buy)
2015-03-16−30,000→ 43,034 total
Exercise: $3.25Exp: 2021-03-27→ Common Stock (30,000 underlying)
Exercise/Conversion
Stock Option (right to buy)
2015-03-16−1,845→ 373,155 total
Exercise: $7.26Exp: 2023-05-13→ Common Stock (1,845 underlying)
Exercise/Conversion
Stock Option (right to buy)
2015-03-16−27,400→ 345,755 total
Exercise: $7.26Exp: 2023-05-13→ Common Stock (27,400 underlying)
Sale
Common Stock
2015-03-16$60.62/sh−2,330$141,245→ 202,752 total
Sale
Common Stock
2015-03-17$58.12/sh−13,300$772,996→ 204,352 total
Exercise/Conversion
Common Stock
2015-03-16$2.36/sh+45,755$107,982→ 248,507 total
Sale
Common Stock
2015-03-16$59.07/sh−23,500$1,388,145→ 218,628 total
Sale
Common Stock
2015-03-16$59.71/sh−13,546$808,832→ 205,082 total

Footnotes (13)

[F1]Includes 457 shares acquired by the Reporting Person on December 10, 2014 pursuant to the Issuer's ESPP.
[F10]The option vests in 36 equal monthly installments and will be fully vested and exercisable on December 27, 2015.
[F11]The exercise price reflects a 3-for-2 stock split effected by the Issuer on March 28, 2014
[F12]The option vests in 48 equal monthly installments and will be fully vested and exercisable on May 14, 2017.
[F13]On March 28, 2014, the Issuer effected a 3-for-2 stock split, resulting in the reporting person's ownership of 125,000 additional options
[F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.44 to $58.41, inclusive.
[F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.46 to $59.45, inclusive.
[F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.46 to $60.41, inclusive.
[F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.46 to $60.86, inclusive.
[F6]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.67 to $57.66, inclusive.
[F7]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.70 to $58.70, inclusive.
[F8]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.73 to $59.20, inclusive.
[F9]The option vests in 48 equal monthly installments and will be fully vested and exercisable on March 28, 2015.

Documents

1 file

4
doc4.xmlPrimary
FORM 4 SUBMISSION

Issuer

Insys Therapeutics, Inc.

CIK 0001516479

→

Entity typeoperating

IncorporatedDE

Related Parties

filerCIK 0001516479

Filing Metadata

Form type: 4
Filed: Mar 17, 8:00 PM ET
Accepted: Mar 18, 4:49 PM ET
Size: 31.6 KB

View on SEC.gov